Table 2.
Correlations between parameters before IFN-free DAA therapy
| AST | ALT | PLT | ALB | APRI | TE | HCV | ATX | sCD14 | sCD163 | Mac2BP | IL-6 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AST | R = 0.881 P < 0.001 |
R = 0.936 P < 0.001 |
R = 0.650 P = 0.016 |
R = 0.591 P = 0.012 |
R = 0.565 P = 0.028 |
|||||||
| ALT | R = 0.881 P < 0.001 |
R = 0.831 P < 0.001 |
R = 0.705 P = 0.007 |
|||||||||
| ALB | R = −0.494 P = 0.05 |
R = −0.631 P = 0.012 |
||||||||||
| PLT | R = −584 P = 0.009 |
R = −0.584 P = 0.022 |
||||||||||
| APRI | R = 0.936 P < 0.001 |
R = 0.831 P < 0.001 |
R = −0.584 P = 0.009 |
R = 0.560 P = 0.049 |
R = 0.750 P = 0.001 |
R = 0.586 P = 0.022 |
||||||
| TE | ||||||||||||
| HCV | ||||||||||||
| ATX | R = −0.494 P = 0.05 |
R = 0.490 P = 0.046 |
R = 0.556 P = 0.01 |
|||||||||
| sCD14 | R = 0.650 P = 0.016 |
R = 0.560 P = 0.049 |
R = 0.490 P = 0.046 |
R = 0.588 P = 0.017 |
||||||||
| sCD163 | R = 0.591 P = 0.012 |
R = −0.584 P = 0.022 |
R = 0.750 P = 0.001 |
|||||||||
| Mac2BP | R = 0.565 P = 0.028 |
R = 0.705 P = 0.007 |
R = 0.586 P = 0.022 |
R = 0.588 P = 0.017 |
R = 0.563 P = 0.040 |
|||||||
| IL-6 | R = −0.631 P = 0.012 |
R = 0.556 P = 0.01 |
R = 0.563 P = 0.040 |
Correlations were determined between clinical parameters (AST, ALT, PLT, ALB, HCV, TE) and soluble markers of immune activation at baseline, before therapy, and those parameters which are significantly correlated (P<0.05) are shown along with correlation coefficient.